Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis

Summary

Study to evaluate the efficacy and safety of JTE-451 administered for 16 weeks in subjects with moderate to severe plaque psoriasis.

Timeline

Start

2019-01-17

Primary completion

2020-03-13

Completion

2020-03-13

Outcome

Met primary endpoint

registry analysis (superiority test); JTE-451 400 mg Twice Daily vs Placebo Twice Daily; p = 0.035; Odds Ratio (OR) 3.74 (95% CI 1.07 to 13.10); NCT03832738 ↗

Drugs

Indications